Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Daily Updates at AndrewNava.com (Focus on ADLR, BPAX, CRIS)

|Includes:ADLS, Alkermes plc (ALKS), ANIP, CASC, CLSN, CRIS, IMMU, NBIX, RDEA, XOMA

Below is today's morning note to clients detailing database updates and new milestones.  The updates are from AndrewNava.com, which currently tracks over 290 publicly-traded biotechnology and pharmaceutical companies, hundreds of clinical trials from more than 1,000 approved and development-stage drugs, devices and diagnostics, and over 700 company milestones across 17 different catalyst types...

Dear Client,

Here are the latest updates at AndrewNava.com...


NEW MILESTONES

ALKS: Vivitrol Psychopharmacologic Drugs AdComm September 16, 2010, PDUFA October 12, 2010 for opioid dependence.
BPAX: Expected enrollment completion for Libigel safety trial 3Q10 with data 3Q11, est enrollment completion for both pivotal trials 4Q10 with data 3Q11; Expected Bio-T-Gel NDA filing YE2010 by Teva.
CRIS: Still on track for several catalysts later this year and into 2011 (includes GDC-0449 ovarian cancer data expected 2H10 and advanced basal cell data expected 2011, as well CUDC-101 data in solid tumors expected at EORTC-NCI-AACR November 2010).

DATABASE UPDATES

IMMU, Clivatuzumab, TF2, Milatuzumab, Epratuzumab, NBIX/Elagolix, CRIS, GDC-0449, ONTY (Stimuvax, PX-866, PX-478), TTNP, TDLP, XOMA 052, CLSN, BTIM, MHAN, ADLS, Celution System, ADLR (ADL5859 and ADL5747), ONCY, RDEA594, ARDM

Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools that focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and powered by our database of clinical trial data and upcoming company milestones.


Disclosure: No positions